Abhoy Sarkar's Avatar
published in Blogs
Apr 16, 2021
Bristol-Myers (BMY, $65.44) gets FDA approval on gastric cancer treatment

Bristol-Myers (BMY, $65.44) gets FDA approval on gastric cancer treatment

Bristol-Myers Squibb  got  approval for Opdivo as a treatment for gastric cancer from the Food and Drug Administration (FDA).

Opdivo as an injection combined with chemotherapy to treat patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. FDA’s approval is based on a Phase 3 trial.

As demonstrated in the … trial, Opdivo is the first and only immunotherapy combined with chemotherapy to deliver superior overall survival versus chemotherapy alone in first-line metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma,”said Adam Lenkowsky, general manager of oncology at the company.

Earlier this week, Truist boosted rating on the pharmaceutical company’s shares to buy from hold, citing optimism about its drug pipeline. Truist hiked price target to $74 a share from $66 on the shares.

Related Tickers: BMY
Related Portfolios: BIOTECHNOLOGY SECTOR